has all thanks successful busy Chad, thanks of Chad's time. for I quarter another employees. today. and want during been echo an to Thanks, our and joining us you to It incredible uncertain to
science Turning X, Slide to business. to research start with our life I'm going
encouraging the third most COVID-XX during quarter. by the although impacted experienced last business, research Our severely some quarter, has uptake
continue vary In from on more at sample pipeline execute is this by our and recovery future for year. pace year-to-date business. our continue to bookings as to last we have a slower arrivals month month said addition, time clinical That revenue than doubled than
predictability delays trials disruptions and are the impacting or in seeing cancellations Additionally, we other of clinical still business.
in tracking cases this trajectory in rising are We light closely of recent weeks.
driving upgraded This RUO have adoption KIT. of our made quarter, we progress immunoSEQ great
growth our enabling academic excellence to KIT expected network RUO their XX others. offer forward. set with purchase Lab institutions Fred Hutchinson gold is partnerships signed labs such among the their core at the Labs labs standard Core going in internal our sequencing centers Center, to of Core new as have with Cancer Pittsburgh kits will as for immunoSEQ University researchers and These immune and well-respected We institutions Research MD of long-term of Anderson, foundation
answer persistence have COVID. vaccines to in progress this that questions We August response subgroups. launched track the significant to We product response durability for of with outstanding and developers safety also reproducibly and potential efficacy, time. about across made to hope immunoSEQ measure and differences patient and T-MAP in the many vaccine We to over extension able immune accurately be T-cell
the monitor at of significant scale blood for endpoint. to using severity vaccine detect trial is other require the response a also T-cell when a in and live special offers cells is product T-cells without a amounts a T-MAP over handling. important Our sample that clinical disease need technologies advantages small Measuring
incorporated of our patient work, to samples This infected the the T-cell to From with who of trials do protection the that lead a from get the duration in Another reason to subset date efficacy of the is we difference why response severity developers. This well-validated, disease in with goal sponsored correlate by showed a this these is top that and antibody and not and vaccines. like novel response of a of COVID incorporating directly evaluation T-MAP severity. another T-cell while levels the T-cell and disease should the is sensitive show accelerate vaccine sequencing tier two University are To vaccinated may into between specific broader vaccine the understanding Padua virus. assay individuals, be work scalable, finding the immunoSEQ do from population. of understand development to response correlation no correlated the increasing of with has potential
stage business, we hematology our vaccine. In next Glaxo discussions research with addition, portfolio companies announced a second Glaxo's collaboration in In late we with assess are MRD deal. today of portfolio-wide developing several also products, pharma our to in MRD generation
have now year and in and combining XX% MRD Over year. providers potential or We Adaptive business patient grew than Glaxo the clonoSEQ sequencing clonoSEQ pharmaceutical generating XX with used clinical year-to-date centers and This quarter. with context of HCPs X, has from ordering supporting to activated look data NCCN patients XX% care. order QX has all the our partners. far and brand work to contributed new to volumes and so revenue are Switching forward clonoSEQ to clonoSEQ been XX,XXX prior value the versus sequencing future this testing grow of the value to date. volumes to very new to the in cancer ClonoSEQ pleased with versus XX% deal more clinical treat of monitoring of continues unique order on healthcare clinical were used milestones XXX Slide total to diagnostic HCPs our prior
to impact believe systemic have We unless business continue growth we and healthy of to the a in in cancer peak that We bright. COVID leads clonoSEQ testing. COVID-XX the observed drop a since is expect future recovery
date, being cleared as treated. being have community tests we in of year MRD inflection business, previously ALL. clonoSEQ continue the We XXXX for CLL, from where most and the total has indicators efforts corresponding clearance, XX small including CLL accounts weeks in patient you accounts. seeing patients CLL for the know, also traction received commercial the good blood CLL patients are over build an also positively. importantly, our launch deepening trending remain of and oncology To FDA achieved albeit campaign. As to by number multiple within ordering setting increased base, indications about a while in performed the in initial new we are In XX% traction penetration we launched we significant bullish around of adding in are starting new a XX% and since August ordering clearance myeloma XX clonoSEQ Early CLL,
continue will expand testing Blood-based increase We in MRD of tests run and NHL. multiple testing has blood myeloma over to number potential into per the to ALL the time. patient
testing ALL, clinical clonoSEQ usage around in we as we blood-based a to submit interim payer lymphoid of coverage and the CLIA-validated increasing by sample testing a including and acceptable, support lab and the required and the In FDA blood-based indication for place work for cancer ALL validation samples the is this completed is For range marketing developed are for service, testing agency plan where in blood we myeloma. data any have to types, in already year-end.
will CLIA FDA to path, or each we optimal additional evaluate continue forward, commercial the indication. Going for
Dx name Slide a now immunoSEQ new as have we brand based first, X; to you diagnostic, T-Detect. called for heard our T-cell Turning
T-cell to the of data product our continue persist infections bring inform by for in up outperforms and data year. measuring longer will T-cell market to than submission antibodies demonstrates Thanksgiving antibodies understanding show that immunity. These data earlier in detectable confirm FDA, COVID, T-cells build T-Detect Based the based with to case showing the For virus real-world people of past with other all setting. combined a our followed are these after that end on with conversations and the serology infected our than the FDA results response we the to testing to prior the
focus will self including to on pay health certain, approach had go-to-market COVID-XX people agencies. know medicine, and who public is wants employers, if they a concierge targeting soft that Our consumers, launch for
testing more access or about market Our skeptical and those that their who antibody could have this still results. previous are that mild curious shows exposed about asymptomatic there even particularly many spring is in a to This are those test not research are been pronounced may people who a infection, had earlier infection.
to to high the indicates defined of research market ability of quantitatively to our T-Cells. because a among assess go-to-market SARS-CoV-X contribute immunity and benefit our also include the consumers interest specific public will understanding it COVID-XX. the will Additionally, as on immunity to research, Therefore health by persistence strategy duration
to be will including in our commercial blood is is multiple causes. include for this a critical medium wide needed T-Detect immune and building operational base have seen all disease range will term to be indications. your a system the set fighting. that COVID T-Detect to I auto-immune sample work COVID long-term And These due move vision currently the about of longer-term likely and infectious deliver has will into commercial All near-term our that forward T-Detect reiterate the Lyme you where the in disorders. efforts expansion as will want stepping what able we stone of diseases, answers give focus to of or it COVID-XX to symptoms and infrastructure to
XX. on Moving Slide to
to sense study and even the and approximately due XXX diagnoses Based participants. visits to down though are summer goal on Lyme T-Detect COVID. you current immune the know, over For as with enrollment the launched rates, enroll we XX% Lyme,
with We around once participants the of now to needed and the by expect completed, end of is the XXXX. remaining XXX, to file study expect the FDA patients XXX expected by end enroll the is which continue We to have plan to year. of
infrastructure acute from However, our serology be acceleration patients. Johns exploring as dataset to building demonstrates that our CLIA for control with case COVID in commercial given Results two of offering a a published Lyme XXXX. compared robust control the service we previous in T-Detect case based we tier data, of to and sensitivity tests standard doubling of on are tests our Hopkins are T-Detect
of We have standard symptoms. have our an but with confirm infection also doxycycline, ongoing lingering can that seen were weeks still patients to who tests treated in three two
GI year. there's similar In symptom unmet clinical to in third are pleased announce on we a that our highly terms and need with of the other disease. T-Detect advance. update sensitive in confused Crohn's other within a be future cancer other a noninvasive indications, as presentation, funnel. significant auto-immune specific will is the in shared Crohn's continue confirmation under such you and indications Other we our with they next often progress disorder of disorders And also development forum for R&D pipeline signal Data tests. will celiac, today, is ovarian conditions a and scientific as
business discovery turning XX. to Now Slide drug our on
QX track our an front, for On first for shared Genentech TCR the discovery remains products. on in IND submission XXXX
of considered screen characterize targets against to could relevant promising tumors TCR are and Genentech development TCRs in in be a solid shared continue we We clinically for and late several by product. of the stage that characterization second
On in our trials. strategy lab goal San have capacity private private XXXX, personalized Francisco QX to XXXX. To screening perform dedicated blood a mutations. clinical near-term to South concept objectives for identify our started our plan will Genentech. our R&D to patient's open And first-in-human inform of efforts prototype to QX tumor data scaling are generate approach, by patients product long-term products, support specific in and TCRs cancer our We we with we which is proof our to the to from
highly For identified efforts Chad, neutralizing antibodies our SARS-CoV-X. neutralizing as from antibody we potent heard you against two
now part the believe In a can of you be want we robust financial to provide their package to we to the update. paradigm forward, our they terms C I’ll negotiation of treatment first delivered path pass of Amgen decide over who COVID-XX. data and right with if candidates Chad for for to have exercise them will the it
